Overtreatment in epilepsy: Adverse consequences and mechanisms

Epilepsy Research

Volumn 52, Issue 1, 2002, Pages 25-33

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Drug interactions; Drug treatment; Epilepsy; Overtreatment; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID;

ANTICONVULSANT THERAPY; BRAIN SURGERY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; FEVER; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NEUROTOXICITY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; RELIABILITY; SEIZURE;

ANTICONVULSANTS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; OVERDOSE; PRESCRIPTIONS, DRUG; TREATMENT FAILURE;

EID: 0036850948     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00182-1     Document Type: Conference Paper

References (44)

1. Bateson A.N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr. Pharm. Des. 8:2002;5-21.
2. Beardsley R.S., Freeman J.M., Appel F.A. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia. 24:1983;330-335.
3. Beghi E., Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties, and perspectives for future research. Drugs. 49:1995;680-694.
4. Berg A.T., Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 44:1994;601-608.
5. Besag F.M.C. Approaches to reducing the incidence of lamotrigine-induced rash. CNS Drugs. 13:2000;21-33.
6. Besag F.M.C., Berry D.J., Pool F., Newbery J.E., Subel K.B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 39:1998;183-187.
7. Biton V., Edwards K.R., Montouris G.D., Sackellares J.C., Harden C.L., Kamin M. Topiramate titration and tolerability. Ann. Pharmacother. 35:2001;173-179.
8. 105 Study Group, Brodie M.J., Yuen A.W.C. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res. 26:1997;423-432.
9. Chadwick D.W. Overuse of monitoring of blood concentrations of antiepileptic drugs. Br. Med. J. 294:1987;723-724.
10. Corda D., Gelisse P., Genton P., Dravet C., Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia. 42:2001;749-754.
11. De Santis A. Diffusion of antiepileptic prophylaxis in Italy. Murri L., Parenti G., Annegers J.F., Pharmacological Prophylaxis for Post-Traumatic Epilepsy. 1991;95-112 Pacini Ed, Pisa.
12. De Santis A., Villani R., Sinisi M., Stocchetti N., Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia. 43:2002;175-182.
13. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 41:2000;1364-1374.
14. Eadie M.J. The role of therapeutic drug monitoring in improving the cost-effectiveness of anticonvulsant therapy. Clin. Pharmacokinet. 29:1995;29-35.
15. Gatti G., Furlanut M., Perucca E. Interindividual variability in the metabolism of antiepileptic drugs and its clinical implications. Pacifici G.M., Pelkonen O., Interindividual Variability in Human Drug Metabolism. 2001;157-180 Taylor and Francis Ltd, London.
16. Guberman A.H., Besag F.M., Brodie M.J., Dooley J.M., Duchowny M.S., Pellock J.M., Richens A., Stems R.S., Trevathan E. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 40:1999;985-991.
17. Hachad H., Ragunau-Majlessi I., Levy R.H. New antiepileptic drugs: review on drug interactions. Ther. Drug. Monit. 24:2002;91-103.
18. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342:2000;314-339.
19. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 42:2001;1255-1260.
20. Laidlaw J., Perucca E., Laidlaw M.V. Less well known manifestations of intoxication from antiepileptic drugs. Manzo L., Lery N., Lacasse Y., Roche L., Advances in Neurotoxicology. 1980;335-338 Pergamon Press, Oxford.
21. Longin E., Teich M., Koelfen W., Konig S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia. 43:2002;451-454.
22. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., Williamson P.D., Treiman D.M., McNamara J.O., McCutchen C.B. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 13:1985;145-151.
23. Nashef I., Fish D.R., Sander J.W., Shorvon S.D. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia. 36:1995;1187-1194.
24. Patsalos P., Froscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia. 43:2002;365-385.
25. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol. Scand. 162 (Suppl):1995;31-34.
26. Perucca E. Pharmacologic advantages of antiepileptic drug monotherapy. Epilepsia. 38:(Suppl. 5):1997;6-8.
27. Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs. 10:1998;171-179.
28. Perucca, E., 2002a. Principles of pharmacotherapy of the epilepsies. In: Asbury, A.K., McKhann, G., McDonald, W.I., Goadsby, P.J., McArthur, J.C. (Eds.), Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles, Cambridge University Press, Cambridge, in press.
29. Perucca, E., 2002b. Predicting the response to antiepileptic drugs: The role of genetic factors. In: Kaneko, S., Motomura, S., Tateishi, T., Kondo, T., Furukawa, K. (Eds.), Pharmacogenetics - Tailor-made Pharmacotherapy. Patient Tailored Drug Therapy, International Congress Series 1094, Elsevier, Amsterdam, in press.
30. Perucca, E., 2002c. What can we learn from clinical trials of new anticonvulsant drugs in epilepsy? Eur. J. Pain. 6 (Suppl. A), 35-44.
31. Perucca E., Grimaldi R., Crema A. Interpretation of drug levels in acute and chronic disease states. Clin. Pharmacokinet. 10:1985;498-513.
32. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia. 39:1998;5-17.
33. Perucca E., Beghi E., Dulac O., Shorvon S.D., Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 41:2000;107-139.
34. Perucca E., Dulac O., Shorvon S., Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs. 15:2001;609-621.
35. Privitera M.D., Brodie M., Nieto W. Topiramate vs investigator choice of carbamazepine or valproate as monotherapy in newly diagnosed epilepsy. Epilepsia. 41:(Suppl. 7):2000;93-94.
36. Pisani F., Oteri G., Russo R., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
37. Reynolds E.H., Shorvon S.D. Monotherapy or polytherapy for epilepsy? Epilepsia. 81:1981;1-10.
38. Richens A., Davidson D.L.W., Cartlidge N.E.F., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J. Neurol. Neurosurg. Psychiatry. 57:1994;682-687.
39. Schmidt D., Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital and carbamazepine: individual variation in relation to seizure type. Neurology. 34:1984;1252-1253.
40. Shorvon S.D., Reynolds E.H. Reduction in polypharmacy for epilepsy. Br. Med. J. 27:1979;1023-1025.
41. Sisodiya S.M., Sander J.W., Patsalos P.N. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 48:2002;217-219.
42. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: metanalysis of controlled trials. Epilepsia. 42:2001;515-524.
43. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother. 33:1999;1037-1042.
44. Woo E., Chan Y.M., Wu Y.K., Chan Y.W., Huang C.Y. If a well stabilised epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomised prospective study. Epilepsia. 29:1989;129-139.